aafq smgt-glp-1 GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation GLP-1 receptor agonists and myocardial
Description
RTA Peptide available in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg options
FDA approves Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity
CagriSema and Amycretin work on the GLP-1 and amylin receptors, Retrarutide on GLP-1, GIP and glucagon, Survodutide, Mazdutide, Pemvidutide and Efinopegdutide on GLP-1 and glucagon and still more are coming
